Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents... Show more
Thermo Fisher Scientific stands as the world leader in serving science, commanding 15-20% market share in the life sciences tools and services sector. Its diversified portfolio spans four key segments: Life Sciences Solutions (including bioproduction reagents), Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. This breadth provides competitive advantages through integrated end-to-end solutions, enabling customers—from pharma giants to academic labs—to accelerate drug discovery and manufacturing.
The company's wide moat stems from scale, R&D investment, and strategic M&A (mergers and acquisitions), allowing it to outpace peers in high-growth areas like gene and cell therapies. Medium-term, TMO's focus on recurring revenue from consumables (over 70% of sales) and customer partnerships positions it resiliently amid industry cycles, with potential for further share gains as biopharma pipelines expand.
The Q1 2026 earnings release on April 23 represents a pivotal near-term event, where management may refine 2026 guidance amid recovering end-markets. Investors will scrutinize updates on Life Sciences Solutions, which showed 13% Q4 2025 growth driven by bioproduction.
Product innovation remains a driver, with recent launches in analytical tools and regulatory wins bolstering the pipeline. Potential strategic partnerships or bolt-on M&A could enhance capabilities in AI-driven drug discovery. Analyst sentiment supports optimism: 22-35 firms rate TMO a consensus Buy/Strong Buy, with recent Barclays target at $625 and highs to $750. Price target revisions have trended stable-to-upward, reflecting confidence in organic growth resumption.
The life sciences instrumentation market is projected to grow at a 6.5% CAGR to $92.5 billion by 2031, fueled by demand for advanced bioprocessing and diagnostics tools—areas where TMO excels. Declining interest rates are easing biopharma funding constraints, spurring capital expenditures on lab equipment. Rising global healthcare spending and technology adoption in genomics further align with TMO's model.
However, TMO remains sensitive to U.S. academic budget cuts and biotech funding droughts, which pressured 2026 profit guidance. Geopolitical risks could disrupt supply chains for instruments, while regulatory shifts in diagnostics may create opportunities or hurdles.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. Designed to spot developing trends, it evaluates possible breakouts or reversals using advanced pattern recognition and historical data analysis. Users can explore predictions across a wide range of tradable instruments, with searchable categories, historical context, and alert functionality for timely insights. This tool empowers informed decision-making in dynamic markets—explore it today for your trading edge.
Thermo Fisher guided 2026 revenue at $46.3-47.2 billion, implying 4-6% growth, with expectations of acceleration to 7%+ by 2028 via bioproduction scale-up. Key themes include market expansion in cell/gene therapies, margin gains from cost efficiencies, and tech transitions like AI in drug development. Consensus forecasts project robust EPS growth, with analysts eyeing $650+ price targets.
Capital allocation prioritizes dividends (recently raised to $0.47/share), buybacks, and M&A. Competitive threats from agile biotech suppliers loom, but TMO's moat and regulatory tailwinds in diagnostics position it strongly. Watch biopharma R&D resurgence and U.S. policy on science funding for sentiment shifts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
a developer of analytical and environment monitoring instruments
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
TMO moved below its 50-day moving average on June 11, 2026 date and that indicates a change from an upward trend to a downward trend. In of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for TMO moved out of overbought territory on June 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMO as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on June 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for TMO crossed bearishly below the 50-day moving average on June 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TMO broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TMO entered a downward trend on May 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in of 318 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.324) is normal, around the industry mean (12.306). P/E Ratio (25.542) is within average values for comparable stocks, (140.469). Projected Growth (PEG Ratio) (1.528) is also within normal values, averaging (1.492). Dividend Yield (0.004) settles around the average of (0.008) among similar stocks. P/S Ratio (3.870) is also within normal values, averaging (7.291).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TMO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.